Published in N Engl J Med on November 15, 2011
Niacin Plus Statin to Prevent Vascular Events | NCT00120289
Effects of Short-term Diet on HDL Composition and Function | NCT03205254
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med (2014) 8.61
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J (2013) 4.87
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol (2013) 3.07
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation (2013) 3.02
The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int (2016) 2.91
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol (2013) 2.60
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med (2012) 2.31
Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol (2015) 2.23
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care (2014) 2.20
Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol (2013) 2.17
High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol (2013) 2.12
Dyslipidemia in obesity: mechanisms and potential targets. Nutrients (2013) 2.02
Contribution of modifiable risk factors to social inequalities in type 2 diabetes: prospective Whitehall II cohort study. BMJ (2012) 1.95
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ (2014) 1.83
Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart (2015) 1.72
High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol (2012) 1.70
Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation (2015) 1.67
Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician (2013) 1.67
Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation (2013) 1.65
Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin Chem (2014) 1.65
Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol (2013) 1.63
Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res (2013) 1.57
Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J (2014) 1.57
Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med (2014) 1.56
MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart (2013) 1.50
Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res (2013) 1.47
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation (2016) 1.43
Low serum high density lipoprotein cholesterol concentration is an independent predictor for enhanced inflammation and endothelial activation. PLoS One (2015) 1.42
Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study. Int J Clin Pract (2013) 1.41
The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Rep (2015) 1.40
Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: a case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). J Clin Lipidol (2014) 1.38
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med (2013) 1.36
G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov (2012) 1.35
An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med (2014) 1.33
Cardioprotective functions of HDLs. J Lipid Res (2013) 1.29
Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med (2012) 1.26
Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.23
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation (2013) 1.20
Novel biological functions of high-density lipoprotein cholesterol. Circ Res (2012) 1.19
Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View. Clin J Am Soc Nephrol (2015) 1.18
Lymphatic transport of high-density lipoproteins and chylomicrons. J Clin Invest (2014) 1.15
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol (2014) 1.14
Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol (2015) 1.11
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol (2013) 1.10
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol (2012) 1.10
MicroRNA expression signature in human abdominal aortic aneurysms. BMC Med Genomics (2012) 1.09
Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism (2012) 1.08
Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol (2012) 1.07
ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res (2015) 1.07
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes (2015) 1.06
Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment. Circ Cardiovasc Qual Outcomes (2012) 1.06
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res (2014) 1.04
Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity (Silver Spring) (2013) 1.04
Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol (2012) 1.03
The perils of surrogate endpoints. Eur Heart J (2015) 1.03
An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway. PLoS Comput Biol (2014) 1.03
Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. J Am Geriatr Soc (2013) 1.03
Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res (2015) 1.03
Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation (2013) 1.02
Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. Eur J Prev Cardiol (2014) 1.00
Racial/ethnic differences in dyslipidemia patterns. Circulation (2013) 0.99
Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem (2014) 0.98
Nitric oxide: considerations for the treatment of ischemic stroke. J Cereb Blood Flow Metab (2012) 0.97
Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care (2012) 0.97
Regulation of signal transduction by HDL. J Lipid Res (2013) 0.97
Overview of omega-3 Fatty Acid therapies. P T (2013) 0.97
Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation (2013) 0.96
Relationships between serum and urine phosphorus with all-cause and cardiovascular mortality: the Osteoporotic Fractures in Men (MrOS) Study. Am J Kidney Dis (2012) 0.96
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J (2013) 0.96
Imaging Atherosclerosis. Circ Res (2016) 0.95
Scan-rescan reproducibility of quantitative assessment of inflammatory carotid atherosclerotic plaque using dynamic contrast-enhanced 3T CMR in a multi-center study. J Cardiovasc Magn Reson (2014) 0.95
High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes (2013) 0.95
Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud (2013) 0.95
HDL and cholesterol: life after the divorce? J Lipid Res (2013) 0.95
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94
Hypercholesterolemia links hematopoiesis with atherosclerosis. Trends Endocrinol Metab (2012) 0.94
MicroRNA control of high-density lipoprotein metabolism and function. Circ Res (2014) 0.93
New cholesterol guidelines: worth the wait? Cleve Clin J Med (2014) 0.93
Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovasc Diabetol (2014) 0.93
Hypertriglyceridemia. Nutrients (2013) 0.92
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J Lipid Res (2014) 0.92
Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. Vasc Health Risk Manag (2014) 0.92
A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion. Trends Pharmacol Sci (2015) 0.91
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud (2013) 0.91
Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics (2013) 0.91
Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study. Atherosclerosis (2013) 0.91
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med (2011) 7.52
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med (2014) 4.88
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens (2014) 3.66
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 3.18
Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation (2003) 3.01
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 2.98
Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol (2012) 2.93
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
The assessment of endothelial function: from research into clinical practice. Circulation (2012) 2.68
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review. Int J Epidemiol (2009) 2.55
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol (2002) 2.41
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21
The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol (2010) 2.18
Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol (2005) 2.16
Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation (2010) 2.13
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension (2012) 2.02
A 300-year-old solution to the health care crisis. Arch Intern Med (2009) 2.01
Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS). Transfusion (2006) 1.91
Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol (2011) 1.91
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91
Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ (2012) 1.86
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol (2013) 1.86
Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med (2009) 1.85
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J (2012) 1.84
Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation (2006) 1.84
Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation (2004) 1.82
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J (2005) 1.79
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation (2011) 1.77
Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol (2008) 1.70
The risks of waiting for cardiac catheterization: a prospective study. CMAJ (2002) 1.70
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care (2010) 1.66
Cardiac arrest survival did not increase in the Resuscitation Outcomes Consortium after implementation of the 2005 AHA CPR and ECC guidelines. Resuscitation (2011) 1.62
Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation (2002) 1.61
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation (2002) 1.60
Cognitive impairment and risk of cardiovascular events and mortality. Eur Heart J (2012) 1.60
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol (2011) 1.58
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial. Circ Cardiovasc Interv (2011) 1.56
Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med (2014) 1.56
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail (2004) 1.54
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52